Safety and efficacy of rodatristat ethyl for the treatment of pulmonary arterial hypertension (ELEVATE-2): a dose-ranging, randomised, multicentre, phase 2b trial
Authors:
- 20 September 2024
- journal article
- research article
- Published by Elsevier in The Lancet Respiratory Medicine
- Vol. 12 (11) , 865-876
Abstract
No abstract availableKeywords
Funding Information
- Sumitomo Pharma America Inc
This publication has 21 references indexed in Scilit:
- The evolution of survival of pulmonary arterial hypertension over 15 yearsPulmonary Circulation, 2022
- Serotonin and Pulmonary Hypertension; Sex and Drugs and ROCK and Rho2022
- Comprehensive review on novel targets and emerging therapeutic modalities for pulmonary arterial HypertensionInternational Journal of Pharmaceutics, 2022
- A trial design to maximize knowledge of the effects of rodatristat ethyl in the treatment of pulmonary arterial hypertension (ELEVATE 2)Pulmonary Circulation, 2022
- Pulmonary Arterial HypertensionNew England Journal of Medicine, 2021
- ONCE DAILY ORAL DOSING OF RODATRISTAT ETHYL (RVT-1201) ACHIEVES REDUCTIONS IN SEROTONIN BIOSYNTHESIS COMPARABLE TO THOSE ASSOCIATED WITH REVERSAL OF VASCULAR REMODELING IN PAH ANIMAL MODELSChest, 2019
- Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary HypertensionThe Journal of Pharmacology and Experimental Therapeutics, 2017
- Gene Therapy by Targeted Adenovirus-mediated Knockdown of Pulmonary Endothelial Tph1 Attenuates Hypoxia-induced Pulmonary HypertensionMolecular Therapy, 2012
- Disruption of the nonneuronal tph1 gene demonstrates the importance of peripheral serotonin in cardiac functionProceedings of the National Academy of Sciences, 2003
- Acute hemodynamic response to the S2-serotonergic receptor antagonist, ketanserin, in patients with primary pulmonary hypertensionInternational Journal of Cardiology, 1987